ArticlePloS one2025
Futility in healthcare among Mexican female patients with breast cancer in advanced stage: The patient perspective.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is the leading cause of cancer-related deaths among women in Mexico, and the outcomes for patients are often poor. Futility in healthcare (FHC) occurs when treatment fails to achieve its intended goals, resulting in negative consequences. This study aimed to estimate the proportion of female patients in Mexico with advanced-stage breast cancer (ABC) who perceive FHC. Additionally, we inform the development and validation of a questionnaire (FHC-Q) to assess this phenomenon. PATIENTS AND
methodsThis cross-sectional study was conducted from May 17, 2024, to December 30, 2024, in three phases. It involved three convenience samples (S) of adult women with ABC: S-1 (n = 30), S-2 (n = 201), and S-3 (n = 257). Phase 1 focused on constructing the FHC-Q, evaluating its content validity (expert agreement), and conducting a pilot test to assess its feasibility, all within S-1. Phase 2 involved assessing the questionnaire's reliability (internal consistency and temporal stability), construct validity (correlations between FHC-Q and DASS21 scores, along with exploratory factor analysis), and criterion validity (correlations between FHC-Q and SF-36 scores), all in S-2. Phase 3 estimated the FHC phenomenon in S-3. The definition of FHC was established using the Delphi method.
resultsParticipants represented typical female Mexican patients with ABC. The FHC-Q comprised 16 items distributed into five dimensions. The FHC-Q demonstrated feasibility and validity, with expert agreement of ≥80% and a five-factor structure explaining 57.8% of the variance. Correlations between the FHC-Q, DASS21 and SF-36 scores were significant and low to moderate. The FHC-Q reliability was confirmed with a Cronbach's alpha of 0.766 and an ICC of 0.845 (95% CI: 0.735-0.909). FHC was perceived by 3.9% of the participants.
conclusionsFHC was perceived by a minority of Mexican women with ABC stages. The FHC-Q was valid, reliable and feasible to assess the phenomenon in the target population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.